Recent developments in autophagy-targeted therapies in cancer

• Published in: Experimental biology and medicine (Maywood, N.J.) Vol. 246; no. 2; pp. 207 - 212
• Main Authors: Jogalekar, Manasi P, Veerabathini, Anurag, Gangadaran, Prakash
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2021
• Subjects: Animals; Autophagy - genetics; Clinical Trials as Topic; Disease Progression; Genes, Tumor Suppressor; Humans; Minireview; Molecular Targeted Therapy; Neoplasms - genetics; Neoplasms - pathology; Neoplasms - therapy; Beclin-1; chloroquine; mTOR; cancer; Autophagy
• ISSN: 1535-3702; 1535-3699; 1535-3699
• DOI: 10.1177/1535370220966545

Autophagy plays a crucial role in cellular development and differentiation as well as in the maintenance of homeostasis in healthy cells. Autophagy is well documented in neurodegenerative disorders, aging, and infectious diseases. However, recognizing its significance in cancer has always been challenging due to its tumor-promoting and suppressive attributes. Various modulators targeting key components of autophagy machinery directly or indirectly have been developed over the years, and have shown promising results in preclinical models. Some of these compounds are even being tested in clinical trials for safety and efficacy. A detailed review of strategies used to target autophagy in cancer is presented including our opinion on developing better therapies and outstanding issues.